bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 337.2% in April

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 240,900 shares, an increase of 337.2% from the March 31st total of 55,100 shares. Based on an average daily volume of 221,200 shares, the short-interest ratio is currently 1.1 days. Approximately 4.4% of the shares of the company are short sold.

bioAffinity Technologies Price Performance

NASDAQ BIAF traded down $0.04 on Friday, hitting $2.37. The stock had a trading volume of 94,849 shares, compared to its average volume of 201,345. bioAffinity Technologies has a one year low of $0.95 and a one year high of $3.62. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.77 and a quick ratio of 1.76. The company’s 50-day moving average is $2.19 and its two-hundred day moving average is $1.73.

bioAffinity Technologies (NASDAQ:BIAF) last posted its earnings results on Monday, April 1st. The company reported ($0.26) EPS for the quarter. bioAffinity Technologies had a negative return on equity of 107.20% and a negative net margin of 313.34%. The firm had revenue of $2.21 million during the quarter.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.